Summary
We have shown that, within therapeutic plasma concentrations, the unbound fraction of furosemide changes in direct proportion to the reciprocal of the plasma albumin concentration (correlation coefficient 0.99). Changes in the albumin concentration were produced by ultrafiltration of human plasma using a haemofiltration filter. Thus, we propose that, when studying changes in the pharmacokinetics of a highly protein bound drug, calculated changes in the unbound fraction offer an alternative to actual measurement of the unbound concentration, which is often difficult.
Nine healthy volunteers receiving a continuous furosemide infusion were studied in normovolaemia and after dehydration (−1.4 kg), with and without pretreatment with an angiotensin converting enzyme inhibitor (captopril) or an a1-adrenoceptor blocking agent (prazosin). Significantly larger changes in the renal clearance of furosemide were found that could be explained by changes in the unbound fraction. Following dehydration, the unbound fraction of furosemide was decreased by about 5%, while its renal clearance fell by 27%, 33% and 13% after pretreatment with placebo, captopril and prazosin, respectively. The secretory clearance of the unbound furosemide changed substantially and in parallel with changes in the renal blood flow. It is suggested that changes in the renal clearance and excretion of furosemide and its t1/2 are much more dependent on changes in renal blood flow than on changes in its unbound fraction.
Similar content being viewed by others
References
Andreasen F, Jakobsen P (1974) Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure. Acta Pharmacol Toxicol 35: 49–57
Odlind B, Beermann B (1980) Renal tubular secretion and effects of furosemide. Clin Pharmacol Ther 27: 784–790
Levy G (1980) Effect of plasma protein binding on renal clearance of drugs. J Pharm Sci 69: 482–483
Jansen JA (1981) Influence of plasma protein binding kinetics on hepatic clearance assessed from a “tube” model and “well-stirred” model. J Pharmacokinet Biopharm 9: 15–26
Bowman RH (1975) Renal secretion [35S]furosemide and its depression by albumin binding. Am J Physiol 229: 93–98
Hall S, Rowland M (1985) Influence of fraction unbound upon the renal clearance of furosemide in the isolated perfused rat kidney. J Pharmacol Exp Ther 232: 263–268
Sjöström P, Odlind B, Beermann B, Hammarlund-Udenaes M (1988) On the mechanism of acute tolerance to furosemide diuresis. Scand J Urol Nephrol 22: 133–140
Führ J, Kaczmarczyk J, Krüttgen C-D (1955) Eine Einfache Colorimetrische Methode zur Inulinbestimmung für Nierenclearanceuntersuchungen bei Stoffwechselgesunden und Diabetikern. Klin Wochenschr 33: 729–730
Brun C (1951) A rapid method for the determination of paraaminohippuric acid in kidney function test. J Lab Clin Med 37: 955–958
Hammarlund MM, Paalzow LK, Odlind B (1984) Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol 26: 197–207
Sjöström P, Odlind B, Beermann B, Hammarlund-Udenaes M (1987) Changes in furosemide pharmacokinetics induced by dehydration. In: Andreucci VE, Dal Canton A (eds) Diuretics: basic pharmacological and clinical aspects. Nijhoff, Dordrecht Boston, USA, pp 107–109
Lee L-J, Cook JA, Smith DE (1986) Renal transport kinetics of furosemide in the isolated perfused rat kidney. J Pharmacokinet Biopharm 14: 157–174
Sjöström P, Odlind B, Beermann B, Karlberg B (1989) Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome. Eur J Clin Pharmacol 37: 173–180
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sjöström, P.A., Kron, B.G. & Odlind, B.G. Changes in renal clearance of furosemide due to changes in renal blood flow and plasma albumin concentration. Eur J Clin Pharmacol 45, 135–139 (1993). https://doi.org/10.1007/BF00315494
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315494